Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ocugen, Inc. | COVAXIN | COVID-19 vaccine | Phase 3 | Ongoing | Intramuscular | COVID-19 |
| Ocugen, Inc. | OCU 300 | Graft Versus Host Disease | Phase 3 | Trial Discontinued | ocular | Immunosuppressant |
| Ocugen, Inc. | OCU410ST - (GARDian3) | Stargardt, Retinitis Pigmentosa 19 (RP19), and Cone-rod dystrophy 3 (CORD3) diseases | Phase 2/3 | Enrollment Initiation | Intravitreal | Genetic Disorder |
| Ocugen, Inc. | BBV152 (OCU-002) - (COVAXIN) | COVID-19 (within U.S.) | Phase 2/3 | Ongoing | Intramuscular | COVID-19 |
| Ocugen, Inc. | OCU410 - (ArMaDa) | Geographic Atrophy (GA) | Phase 2 | Ongoing | Intravitreal | Opthalmic |
| Ocular Therapeutix Inc. | AXPAXLI (OTX-TKI) - (SOL-R) | Wet age-related macular degeneration (wet AMD) | Phase 3 | Ongoing | intravitreal injection | Opthalmic |
| Ocular Therapeutix Inc. | AXPAXLI (OTX-TKI) - (SOL-1) | Wet Age-related Macular Degeneration (AMD) | Phase 3 | Ongoing | intravitreal injection | Opthalmic |
| Ocular Therapeutix Inc. | AXPAXLI (OTX-TKI) - (SOL-X) | wet AMD | Phase 3 | Trial Planned | intravitreal injection | Opthalmic |
